NCT03035227 (ABLATE-CRT) is a Phase 4 clinical trial of Catheter Ablation in Arrhythmia, Cardiac, sponsored by Kansas City Heart Rhythm Institute.

Who is sponsoring NCT03035227?

NCT03035227 is sponsored by Kansas City Heart Rhythm Institute.

What drugs are being tested in NCT03035227?

Interventions in NCT03035227: Catheter Ablation, Anti-Arrhythmics.

What condition does NCT03035227 study?

NCT03035227 studies Arrhythmia, Cardiac.

Is NCT03035227 still recruiting?

NCT03035227 is currently terminated. Last updated 10 September 2022.

Are results published for NCT03035227?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-09-10 · How we verify

NCT03035227: ABLATE-CRT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Catheter Ablation of Arrhythmias to Improve CRT Response

Terminated Phase 4 Results posted Last updated 10 September 2022

What this trial tests

Phase 4 trial testing Catheter Ablation in Arrhythmia, Cardiac in 2 participants. Terminated before completion.

Timeline

23 January 2017

Primary endpoint
1 May 2018

1 May 2018

Quick facts

Lead sponsor	Kansas City Heart Rhythm Institute
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	2
Start date	23 January 2017
Primary completion	1 May 2018
Estimated completion	1 May 2018
Sites	1 location across United States

Drugs / interventions tested

Catheter Ablation
Anti-Arrhythmics

Conditions studied

Arrhythmia, Cardiac — all drugs for Arrhythmia, Cardiac →

Sponsor

Kansas City Heart Rhythm Institute

Who can join

Adults 18 to 80, any sex, with Arrhythmia, Cardiac. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test if catheter ablation is better than medication therapy at treating arrhythmias originating from the upper and/or lower chambers of the heart in order to allow the heart to beat properly.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Catheter Ablation

Trials testing the same drug.

NCT07403760 — Wellbeing and Survival Improvement With Event Reduction by Ablation for Atrial Fibrillation in the Very Elderly · NA · recruiting
NCT07017855 — Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia · NA · not yet recruiting
NCT06747091 — ARIADNE Clinical Trial · NA · recruiting
NCT07096219 — Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a · enrolling by invitation
NCT06505798 — Cryoballoon/Radiofrequency/Pulsed Field Ablation of Atrial Fibrillation Versus Medical Treatment for Heart · NA · recruiting

Other recruiting trials for Arrhythmia, Cardiac

Currently open trials in the same condition.

NCT04345627 — Japanese Lead Extraction Registry · recruiting

Other Kansas City Heart Rhythm Institute trials

Trials by the same sponsor.

NCT04361838 — The COVID-19 ICU PRAYER Study · NA · terminated
NCT02666742 — DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03035227 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kansas City Heart Rhythm Institute
Last refreshed: 10 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03035227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing